[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615837":3},{"organization":4,"outcomesModule":7,"designInfo":38,"detailedDescription":11,"studyPopulation":11,"armGroups":49,"interventions":65,"overallOfficials":11,"centralContacts":73,"locations":79,"responsibleParty":98,"collaborators":11,"id":100,"slug":11,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":11,"eligibilityCriteria":105,"healthyVolunteers":101,"sex":106,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":11,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":11,"overallStatus":82,"whyStopped":11,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Fujian Shengdi Pharmaceutical Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Change from baseline in 24-hour mean systolic blood pressure assessed by ABPM at month 6",null,"at 6 months after initiation of administration",[14,17,20,22,24,26,28,30,32,34,36],{"measure":15,"description":11,"timeFrame":16},"Change from baseline in 24-hour mean systolic blood pressure assessed by ABPM at month 3","at 3 months after initiation of administration",{"measure":18,"description":11,"timeFrame":19},"Change from baseline in 24-hour mean systolic blood pressure assessed by ABPM at month 9","at 9 months after initiation of administration",{"measure":21,"description":11,"timeFrame":16},"Change from baseline in 24-hour mean diastolic blood pressure assessed by ABPM at month 3",{"measure":23,"description":11,"timeFrame":12},"Change from baseline in 24-hour mean diastolic blood pressure assessed by ABPM at month 6",{"measure":25,"description":11,"timeFrame":19},"Change from baseline in 24-hour mean diastolic blood pressure assessed by ABPM at month 9",{"measure":27,"description":11,"timeFrame":16},"Change from baseline in mean sitting office systolic blood pressure at month 3;",{"measure":29,"description":11,"timeFrame":12},"Change from baseline in mean sitting office systolic blood pressure at month 6;",{"measure":31,"description":11,"timeFrame":19},"Change from baseline in mean sitting office systolic blood pressure at month 9;",{"measure":33,"description":11,"timeFrame":16},"Change from baseline in mean sitting office diastolic blood pressure at month 3;",{"measure":35,"description":11,"timeFrame":12},"Change from baseline in mean sitting office diastolic blood pressure at month 6;",{"measure":37,"description":11,"timeFrame":19},"Change from baseline in mean sitting office diastolic blood pressure at month 9;",{"allocation":39,"interventionModel":40,"interventionModelDescription":11,"primaryPurpose":41,"observationalModel":11,"timePerspective":11,"maskingInfo":42},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":43,"maskingDescription":11,"whoMasked":44},"QUADRUPLE",[45,46,47,48],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[50,56,59,62],{"label":51,"type":52,"description":11,"interventionNames":53},"Treatment group A: HRS-9563 or Placebo Injection; low dose","EXPERIMENTAL",[54,55],"Drug: HRS-9563 Injection","Drug: sodium chloride injection",{"label":57,"type":52,"description":11,"interventionNames":58},"Treatment group B: HRS-9563 or Placebo Injection; Intermediate dose",[54,55],{"label":60,"type":52,"description":11,"interventionNames":61},"Treatment group C: HRS-9563 or Placebo Injection; Medium to high dose",[54,55],{"label":63,"type":52,"description":11,"interventionNames":64},"Treatment group D: HRS-9563 or Placebo Injection; high dose",[54,55],[66,70],{"type":67,"name":68,"description":68,"armGroupLabels":69,"otherNames":11},"DRUG","HRS-9563 Injection",[51,57,60,63],{"type":67,"name":71,"description":71,"armGroupLabels":72,"otherNames":11},"sodium chloride injection",[51,57,60,63],[74],{"name":75,"role":76,"phone":77,"phoneExt":11,"email":78},"Yuhan Guo","CONTACT","+0518-81220121","yuhan.guo.yg21@hengrui.com",[80],{"facility":81,"status":82,"city":83,"state":84,"zip":85,"country":86,"countryCode":87,"cosmosGeoPoint":88,"geoPoint":93,"contacts":94},"Beijing Anzhen Hospital, Capital Medical University","RECRUITING","Beijing","Beijing Municipality","100029","China","CN",{"type":89,"coordinates":90},"Point",[91,92],116.39723,39.9075,{"lat":92,"lon":91},[95],{"name":96,"role":97,"phone":11,"phoneExt":11,"email":11},"Jun Cai","PRINCIPAL_INVESTIGATOR",{"type":99,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100615837",false,"NCT07297797","Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-9563 in Patients With Mild to Moderate Hypertension","Inclusion Criteria:\n\n1. The subject voluntarily signs the informed consent form.\n2. Male or female, aged ≥ 18 years and ≤ 75 years;\n3. Patients with mild to moderate hypertension;\n4. At the Screening and Baseline periods, the mean sitting office systolic blood pressure is \\> 130 mmHg, and the 24-hour mean systolic blood pressure assessed by ABPM at Screening is ≥ 130 mmHg and \\\u003C 160 mmHg.\n\nExclusion Criteria:\n\n1. Secondary hypertension;\n2. Orthostatic hypotension;\n3. Type 1 diabetes or poorly controlled type 2 diabetes;\n4. Occurrence of any cardiovascular or cerebrovascular event within 6 months prior to screening;\n5. Presence of uncontrolled severe arrhythmia within 6 months prior to screening;\n6. Suspected allergy to the investigational drug or any of its components;\n7. Other diseases requiring Renin-Angiotensin-Aldosterone System (RAAS) inhibitor therapy, besides hypertension;\n8. Any blood biochemical indicator during screening or baseline did not meet the standards in the exclusion criteria;\n9. Use of any medication affecting blood pressure within 4 weeks prior to screening, or planned use during the study period;","ALL","18 Years","75 Years",{"count":110,"type":111},234,"ESTIMATED","INTERVENTIONAL",[114],"PHASE2","This study aims to evaluate the efficacy and safety of HRS-9563 in patients with mild to moderate hypertension, and to explore its appropriate dosage.",[117],"Mild to Moderate Hypertension","2026-01-23",{"date":120,"type":121},"2026-01-26","ACTUAL",{"date":123,"type":121},"2026-01-14",{"date":125,"type":111},"2027-10",{"name":5,"class":6},1]